Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
April 08 2013 - 7:00AM
Marketwired
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based
multi-product pharmaceutical company producing generic antibiotics
and specialty pharmaceuticals in addition to its own line of
proprietary products, today announces that ZAO "Rafarma" has
registered (MHH) CEFTRIAXONE, a third-generation cephalosporin
antibiotic, as a medication under international unpatented label.
CEFTRIAXONE is most often used in combination for the treatment
of pneumonia, bacterial meningitis, gonorrhea, and in pediatrics
for the prevention of sepsis. Market capacity of CEFTRIAXONE in the
Russian Federation in 2012 was USD $85.7 million dollars, an
increase of 20% compared to its capacity in 2011.
Dave Anderson, CEO of Rafarma Pharmaceuticals, said,
"Registering this product is complementary to our goal of producing
high-quality pharmaceutical products. Rafarma is positioned to meet
rising market demand for CEFTRIAXONE utilizing our state-of-the-art
research facility and staff as we continue efforts to expand our
product portfolio."
"I'd also like to clarify that Rafarma's earlier announcement
reporting its status as 1 of 4 National Strategic Pharmaceutical
Suppliers to the Russian Federation in no way limits our ability to
produce and manufacture products for qualified buyers globally,"
added Mr. Anderson. "We will offer CEFTRIAXONE, as well as all
other products we produce, to the international market."
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma
Pharmaceuticals produces generic antibiotics and specialty
pharmaceuticals in addition to its own line of proprietary products
that are approved by the Ministry of Health of Russian Federation.
For the last three years the Russian Government has been highly
focused on bolstering the development of nation's domestic
pharmaceutical industry. Rafarma Pharmaceuticals' mission is to
work with the auspices of aggressive federal initiatives to
fast-track the modernization of Russia's pharmaceutical
industry.
To view additional information on Rafarma Pharmaceuticals,
visit: www.rafarma.com
To like our Facebook page or follow us on Twitter for company
updates and industry related news, visit:
www.facebook.com/Rafarmainfo and www.twitter.com/Rafarmainfo
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may," "future," "plan" or "planned," "will" or "should,"
"expected," "anticipates," "draft," "eventually" or "projected."
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in our annual report and/or other releases made by us.
You should consider these factors in evaluating the forward-looking
statements included herein, and not place undue reliance on such
statements. The forward-looking statements in this release are made
as of the date hereof and Rafarma Pharmaceuticals, Inc. undertakes
no obligation to update such statements.
Contact: Rafarma Pharmaceuticals Dave Anderson Chief Executive
Officer (801) 540-210-7135 www.Rafarma.com IR@Rafarma.com
QualityStocks Scottsdale, Arizona www.QualityStocks.com
480.374.1336 Office Editor@QualityStocks.net
Rafarma Pharmaceuticals (PK) (USOTC:RAFA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rafarma Pharmaceuticals (PK) (USOTC:RAFA)
Historical Stock Chart
From Sep 2023 to Sep 2024